Esperion Therapeutics Stock Investor Sentiment

ESPR Stock  USD 1.54  0.04  2.67%   
Slightly above 68 percent of all Esperion Therapeutics' retail investors are curious in acquiring. The analysis of the overall investor sentiment regarding Esperion Therapeutics suggests that quite a few traders are confidant. Esperion Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Esperion Therapeutics. Many technical investors use Esperion Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Comfort Level 68

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Esperion Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Esperion Therapeutics.

Esperion Historical Sentiment

Although Esperion Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Esperion, such as negative comments on social media and news outlets, may cause fear in the market and push Esperion Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Esperion.
  

Esperion Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Esperion Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Esperion Therapeutics chief commercial officer sells shares worth 410 - Investing.com
Google News at Macroaxis
over six months ago at aol.com         
Disposition of 211 shares by Warren Eric of Esperion Therapeutics at 1.946 subject to Rule 16b-3
news
over six months ago at aol.com         
Be Proactive to Prevent Heart Attacks and Strokes
news
over six months ago at www.macroaxis.com         
Acquisition by Shepard Jay of 23000 shares of Esperion Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
19th Annual Cardiometabolic Health Congress Honoring the Life and Legacy of CMHC Co-Chair Dr. George...
Yahoo News
over six months ago at insidermonkey.com         
Esperion Therapeutics, Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over six months ago at investing.com         
Earnings call Esperion reports strong Q2 growth with cardiovascular therapies
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Tesco pilots Digital Product Passports for FF clothing range
Yahoo News
over six months ago at gurufocus.com         
Esperion Therapeutics Inc Q2 2024 Earnings Call Transcript Highlights Strong Revenue ...
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Esperions Q2 Loss Narrows, Revenues Soar Year Over Year
Yahoo News
over six months ago at investorplace.com         
ESPR Stock Earnings Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
sbwire news
over six months ago at gurufocus.com         
Esperion Therapeutics Inc Q2 2024 Earnings Revenue Surges to 73.8 Million, EPS Misses Estimates
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Esperion Therapeutics Reports Q2 Loss, Tops Revenue Estimates
Yahoo News
over six months ago at seekingalpha.com         
Earnings summary Esperion Therapeutics reports mixed Q2 results reaffirms FY24 outlook
seekingalpha News
over six months ago at finance.yahoo.com         
Esperion Therapeutics Q2 Earnings Snapshot
Yahoo News
Far too much social signal, news, headlines, and media speculation about Esperion Therapeutics that are available to investors today. That information is available publicly through Esperion media outlets and privately through word of mouth or via Esperion internal channels. However, regardless of the origin, that massive amount of Esperion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Esperion Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Esperion Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Esperion Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Esperion Therapeutics alpha.

Esperion Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 12447 shares by Sheldon Koenig of Esperion Therapeutics at 2.466 subject to Rule 16b-3
12/17/2024
2
Acquisition by Benjamin Looker of 20500 shares of Esperion Therapeutics subject to Rule 16b-3
12/20/2024
3
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
01/02/2025
4
Disposition of 123 shares by Warren Eric of Esperion Therapeutics at 2.26 subject to Rule 16b-3
01/17/2025
5
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635
02/13/2025
6
Disposition of tradable shares by Halladay Benjamin of Esperion Therapeutics at 1.86 subject to Rule 16b-3
02/19/2025
7
Will Esperion Therapeutics Report Negative Earnings Next Week What You Should Know
02/25/2025
8
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL b
03/03/2025
9
Esperion Therapeutics GAAP EPS of -0.11 beats by 0.04, revenue of 69.11M beats by 7.53M
03/04/2025
10
ESPRs Q4 Loss Narrower Than Expected, Revenues Increase YY
03/05/2025
11
Esperion stock hits 52-week low at 1.55 amid market challenges - Investing.com
03/11/2025

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.